{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:33Z","timestamp":1784851233999,"version":"3.55.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02854-7","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:01:08Z","timestamp":1784847668000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kr\u00fcppel-like factor 4 downregulation during esophageal cancer formation facilitates immune evasion and impairs immunotherapy"],"prefix":"10.1038","volume":"11","author":[{"given":"Xiao","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglin","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8723-8868","authenticated-orcid":false,"given":"Dongxin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4954-1011","authenticated-orcid":false,"given":"Chen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2854_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2854_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan, E. et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology 163, 649\u2013658.e642 (2022).","journal-title":"Gastroenterology"},{"key":"2854_CR3","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/S0140-6736(24)02226-8","volume":"404","author":"H Yang","year":"2024","unstructured":"Yang, H. et al. Oesophageal cancer. Lancet 404, 1991\u20132005 (2024).","journal-title":"Lancet"},{"key":"2854_CR4","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma, P. et al. Immune checkpoint therapy-current perspectives and future directions. Cell 186, 1652\u20131669 (2023).","journal-title":"Cell"},{"key":"2854_CR5","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838\u2013857 (2021).","journal-title":"Cancer Discov."},{"key":"2854_CR6","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo, H. et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA 326, 916\u2013925 (2021).","journal-title":"JAMA"},{"key":"2854_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu, J. et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 24, 483\u2013495 (2023).","journal-title":"Lancet Oncol."},{"key":"2854_CR8","doi-asserted-by":"publisher","first-page":"e068714","DOI":"10.1136\/bmj-2021-068714","volume":"377","author":"Z Lu","year":"2022","unstructured":"Lu, Z. et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ 377, e068714 (2022).","journal-title":"BMJ"},{"key":"2854_CR9","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly, R. J. et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N. Engl. J. Med. 384, 1191\u20131203 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2854_CR10","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.medj.2024.05.016","volume":"5","author":"M Alsina","year":"2024","unstructured":"Alsina, M. & Fleitas-Kanonnikoff, T. Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma. Med 5, 1038\u20131040 (2024).","journal-title":"Med"},{"key":"2854_CR11","doi-asserted-by":"crossref","unstructured":"Yang, Y. et al. Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China. Dis. Esophagus 35, doac031 (2022).","DOI":"10.1093\/dote\/doac031"},{"key":"2854_CR12","doi-asserted-by":"publisher","first-page":"112558","DOI":"10.1016\/j.intimp.2024.112558","volume":"138","author":"Y Guo","year":"2024","unstructured":"Guo, Y. et al. Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study. Int Immunopharmacol. 138, 112558 (2024).","journal-title":"Int Immunopharmacol."},{"key":"2854_CR13","doi-asserted-by":"publisher","first-page":"975986","DOI":"10.3389\/fimmu.2022.975986","volume":"13","author":"P Fang","year":"2022","unstructured":"Fang, P. et al. Immunotherapy resistance in esophageal cancer: possible mechanisms and clinical implications. Front Immunol. 13, 975986 (2022).","journal-title":"Front Immunol."},{"key":"2854_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41577-020-0390-6","volume":"21","author":"D Dersh","year":"2021","unstructured":"Dersh, D., Holly, J. & Yewdell, J. W. A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat. Rev. Immunol. 21, 116\u2013128 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"2854_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala, S., Hammer, C. & Delamarre, L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat. Rev. Cancer 21, 298\u2013312 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2854_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov, H., Orhan, A., Christensen, J. P. & Gogenur, I. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br. J. Cancer 124, 359\u2013367 (2021).","journal-title":"Br. J. Cancer"},{"key":"2854_CR17","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1158\/1078-0432.CCR-21-3501","volume":"28","author":"N Aptsiauri","year":"2022","unstructured":"Aptsiauri, N. & Garrido, F. The challenges of HLA class I loss in cancer immunotherapy: facts and hopes. Clin. Cancer Res. 28, 5021\u20135029 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2854_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney, M. S. et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48\u201361 (2015).","journal-title":"Cell"},{"key":"2854_CR19","doi-asserted-by":"crossref","unstructured":"Rodig, S. J. et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci. Transl. Med. 10, eaar3342 (2018).","DOI":"10.1126\/scitranslmed.aar3342"},{"key":"2854_CR20","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger, S. et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 7, 1420\u20131435 (2017).","journal-title":"Cancer Discov."},{"key":"2854_CR21","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy, K., Colbert, J. D. & Rock, K. L. Cancer immune evasion through loss of MHC class I antigen presentation. Front. Immunol. 12, 636568 (2021).","journal-title":"Front. Immunol."},{"key":"2854_CR22","doi-asserted-by":"publisher","first-page":"20009","DOI":"10.1074\/jbc.271.33.20009","volume":"271","author":"JM Shields","year":"1996","unstructured":"Shields, J. M., Christy, R. J. & Yang, V. W. Identification and characterization of a gene encoding a gut-enriched Kruppel-like factor expressed during growth arrest. J. Biol. Chem. 271, 20009\u201320017 (1996).","journal-title":"J. Biol. Chem."},{"key":"2854_CR23","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S1357-2725(00)00059-5","volume":"32","author":"DT Dang","year":"2000","unstructured":"Dang, D. T., Pevsner, J. & Yang, V. W. The biology of the mammalian Kruppel-like family of transcription factors. Int. J. Biochem Cell Biol. 32, 1103\u20131121 (2000).","journal-title":"Int. J. Biochem Cell Biol."},{"key":"2854_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663\u2013676 (2006).","journal-title":"Cell"},{"key":"2854_CR25","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1053\/j.gastro.2005.02.022","volume":"128","author":"JP Katz","year":"2005","unstructured":"Katz, J. P. et al. Loss of Klf4 in mice causes altered proliferation and differentiation and precancerous changes in the adult stomach. Gastroenterology 128, 935\u2013945 (2005).","journal-title":"Gastroenterology"},{"key":"2854_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1053\/j.gastro.2010.03.048","volume":"139","author":"MP Tetreault","year":"2010","unstructured":"Tetreault, M. P. et al. Esophageal squamous cell dysplasia and delayed differentiation with deletion of kruppel-like factor 4 in murine esophagus. Gastroenterology 139, 171\u2013181.e179 (2010).","journal-title":"Gastroenterology"},{"key":"2854_CR27","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.molonc.2012.12.002","volume":"7","author":"N Mohan","year":"2013","unstructured":"Mohan, N. et al. KLF4 overexpression and apigenin treatment down regulated anti-apoptotic Bcl-2 proteins and matrix metalloproteinases to control growth of human malignant neuroblastoma SK-N-DZ and IMR-32 cells. Mol. Oncol. 7, 464\u2013474 (2013).","journal-title":"Mol. Oncol."},{"key":"2854_CR28","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/sj.onc.1210022","volume":"26","author":"AM Ghaleb","year":"2007","unstructured":"Ghaleb, A. M. et al. Kruppel-like factor 4 exhibits antiapoptotic activity following gamma-radiation-induced DNA damage. Oncogene 26, 2365\u20132373 (2007).","journal-title":"Oncogene"},{"key":"2854_CR29","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3748\/wjg.v8.i6.966","volume":"8","author":"N Wang","year":"2002","unstructured":"Wang, N. et al. Down-regulation of gut-enriched Kruppel-like factor expression in esophageal cancer. World J. Gastroenterol. 8, 966\u2013970 (2002).","journal-title":"World J. Gastroenterol."},{"key":"2854_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41420-023-01416-y","volume":"9","author":"Z He","year":"2023","unstructured":"He, Z., He, J. & Xie, K. KLF4 transcription factor in tumorigenesis. Cell Death Discov. 9, 118 (2023).","journal-title":"Cell Death Discov."},{"key":"2854_CR31","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1158\/1078-0432.CCR-09-0310","volume":"15","author":"W Hu","year":"2009","unstructured":"Hu, W. et al. Putative tumor-suppressive function of Kruppel-like factor 4 in primary lung carcinoma. Clin. Cancer Res 15, 5688\u20135695 (2009).","journal-title":"Clin. Cancer Res"},{"key":"2854_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/cdd.2015.85","volume":"23","author":"T Yu","year":"2016","unstructured":"Yu, T. et al. KLF4 regulates adult lung tumor-initiating cells and represses K-Ras-mediated lung cancer. Cell Death Differ. 23, 207\u2013215 (2016).","journal-title":"Cell Death Differ."},{"key":"2854_CR33","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1038\/s41418-019-0458-7","volume":"27","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. The deubiquitinase USP10 regulates KLF4 stability and suppresses lung tumorigenesis. Cell Death Differ. 27, 1747\u20131764 (2020).","journal-title":"Cell Death Differ."},{"key":"2854_CR34","doi-asserted-by":"publisher","first-page":"15566","DOI":"10.18632\/aging.103592","volume":"12","author":"M Xue","year":"2020","unstructured":"Xue, M. et al. The association between KLF4 as a tumor suppressor and the prognosis of hepatocellular carcinoma after curative resection. Aging 12, 15566\u201315580 (2020).","journal-title":"Aging"},{"key":"2854_CR35","doi-asserted-by":"publisher","first-page":"953","DOI":"10.7150\/ijbs.30857","volume":"15","author":"L Li","year":"2019","unstructured":"Li, L. et al. KLF4-mediated CDH3 upregulation suppresses human hepatoma cell growth and migration via GSK-3beta signaling. Int. J. Biol. Sci. 15, 953\u2013961 (2019).","journal-title":"Int. J. Biol. Sci."},{"key":"2854_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2479-z","volume":"11","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. KLF4-mediated upregulation of CD9 and CD81 suppresses hepatocellular carcinoma development via JNK signaling. Cell Death Dis. 11, 299 (2020).","journal-title":"Cell Death Dis."},{"key":"2854_CR37","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3233\/CBM-160660","volume":"17","author":"Z Yang","year":"2016","unstructured":"Yang, Z. et al. BIRC7 and KLF4 expression in benign and malignant lesions of pancreas and their clinicopathological significance. Cancer Biomark. 17, 437\u2013444 (2016).","journal-title":"Cancer Biomark."},{"key":"2854_CR38","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-17-0387","volume":"23","author":"VK Xie","year":"2017","unstructured":"Xie, V. K. et al. DNA-methyltransferase 1 induces dedifferentiation of pancreatic cancer cells through silencing of Kruppel-like factor 4 expression. Clin. Cancer Res. 23, 5585\u20135597 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2854_CR39","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1158\/0008-5472.CAN-04-3619","volume":"65","author":"D Wei","year":"2005","unstructured":"Wei, D. et al. Drastic down-regulation of Kruppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res. 65, 2746\u20132754 (2005).","journal-title":"Cancer Res."},{"key":"2854_CR40","doi-asserted-by":"publisher","first-page":"6395","DOI":"10.1158\/1078-0432.CCR-06-1034","volume":"12","author":"M Kanai","year":"2006","unstructured":"Kanai, M. et al. Loss of Kruppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression. Clin. Cancer Res. 12, 6395\u20136402 (2006).","journal-title":"Clin. Cancer Res."},{"key":"2854_CR41","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/cas.14341","volume":"111","author":"Z Rong","year":"2020","unstructured":"Rong, Z. et al. GINS complex subunit 4, a prognostic biomarker and reversely mediated by Kruppel-like factor 4, promotes the growth of colorectal cancer. Cancer Sci. 111, 1203\u20131217 (2020).","journal-title":"Cancer Sci."},{"key":"2854_CR42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1158\/1541-7786.MCR-18-0399","volume":"17","author":"VW Yang","year":"2019","unstructured":"Yang, V. W. et al. Increased genetic instability and accelerated progression of colitis-associated colorectal cancer through intestinal epithelium-specific deletion of Klf4. Mol. Cancer Res 17, 165\u2013176 (2019).","journal-title":"Mol. Cancer Res"},{"key":"2854_CR43","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/sj.onc.1207067","volume":"23","author":"W Zhao","year":"2004","unstructured":"Zhao, W. et al. Identification of Kruppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene 23, 395\u2013402 (2004).","journal-title":"Oncogene"},{"key":"2854_CR44","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.ccell.2023.03.001","volume":"41","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Epithelial cells activate fibroblasts to promote esophageal cancer development. Cancer Cell 41, 903\u2013918 e908 (2023).","journal-title":"Cancer Cell"},{"key":"2854_CR45","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ccell.2025.02.009","volume":"43","author":"J Chang","year":"2025","unstructured":"Chang, J. et al. Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis. Cancer Cell 43, 380\u2013397.e387 (2025).","journal-title":"Cancer Cell"},{"key":"2854_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17492-y","volume":"11","author":"J Yao","year":"2020","unstructured":"Yao, J. et al. Single-cell transcriptomic analysis in a mouse model deciphers cell transition states in the multistep development of esophageal cancer. Nat. Commun. 11, 3715 (2020).","journal-title":"Nat. Commun."},{"key":"2854_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25539-x","volume":"12","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis. Nat. Commun. 12, 5291 (2021).","journal-title":"Nat. Commun."},{"key":"2854_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32566-9","volume":"13","author":"JR Moonen","year":"2022","unstructured":"Moonen, J. R. et al. KLF4 recruits SWI\/SNF to increase chromatin accessibility and reprogram the endothelial enhancer landscape under laminar shear stress. Nat. Commun. 13, 4941 (2022).","journal-title":"Nat. Commun."},{"key":"2854_CR49","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.4049\/jimmunol.1601679","volume":"198","author":"V Ramsuran","year":"2017","unstructured":"Ramsuran, V. et al. Sequence and Phylogenetic Analysis of the Untranslated Promoter Regions for HLA Class I Genes. J. Immunol. 198, 2320\u20132329 (2017).","journal-title":"J. Immunol."},{"key":"2854_CR50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.molimm.2017.12.005","volume":"113","author":"MLM Jongsma","year":"2019","unstructured":"Jongsma, M. L. M., Guarda, G. & Spaapen, R. M. The regulatory network behind MHC class I expression. Mol. Immunol. 113, 16\u201321 (2019).","journal-title":"Mol. Immunol."},{"key":"2854_CR51","doi-asserted-by":"crossref","unstructured":"Hazini, A., Fisher, K. & Seymour, L. Deregulation of HLA-I in cancer and its central importance for immunotherapy. J. Immunother. Cancer. 9, e002899 (2021).","DOI":"10.1136\/jitc-2021-002899"},{"key":"2854_CR52","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1161\/ATVBAHA.111.244962","volume":"32","author":"XH Zhang","year":"2012","unstructured":"Zhang, X. H. et al. TGF-beta1 downregulates AT1 receptor expression via PKC-delta-mediated Sp1 dissociation from KLF4 and Smad-mediated PPAR-gamma association with KLF4. Arterioscler Thromb. Vasc. Biol. 32, 1015\u20131023 (2012).","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"2854_CR53","first-page":"300","volume":"46","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. EOFAZ inhibits endothelial\u2011to\u2011mesenchymal transition through downregulation of KLF4. Int. J. Mol. Med. 46, 300\u2013310 (2020).","journal-title":"Int. J. Mol. Med."},{"key":"2854_CR54","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.ccell.2023.08.014","volume":"41","author":"V Ferrari","year":"2023","unstructured":"Ferrari, V. et al. Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I. Cancer Cell 41, 1717\u20131730.e1714 (2023).","journal-title":"Cancer Cell"},{"key":"2854_CR55","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2326-6066.CIR-24-0484","volume":"13","author":"J Sun","year":"2025","unstructured":"Sun, J. et al. Blocking WNT7A enhances MHC-I antigen presentation and enhances the effectiveness of immune checkpoint blockade therapy. Cancer Immunol. Res. 13, 400\u2013416 (2025).","journal-title":"Cancer Immunol. Res."},{"key":"2854_CR56","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bbrc.2015.10.163","volume":"468","author":"S Stavri","year":"2015","unstructured":"Stavri, S., Simionescu, M., Kardassis, D. & Gafencu, A. V. Kruppel-like factor 4 synergizes with CREB to increase the activity of apolipoprotein E gene promoter in macrophages. Biochem. Biophys. Res Commun. 468, 66\u201372 (2015).","journal-title":"Biochem. Biophys. Res Commun."},{"key":"2854_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1290684","volume":"14","author":"FQ An","year":"2023","unstructured":"An, F. Q. et al. KLF4 and CD55 expression and function depend on each other. Front. Immunol. 14, 1290684 (2023).","journal-title":"Front. Immunol."},{"key":"2854_CR58","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/ng0893-341","volume":"4","author":"J Zucman","year":"1993","unstructured":"Zucman, J. et al. EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat. Genet. 4, 341\u2013345 (1993).","journal-title":"Nat. Genet."},{"key":"2854_CR59","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/35085068","volume":"2","author":"B Mayr","year":"2001","unstructured":"Mayr, B. & Montminy, M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev. Mol. Cell Biol. 2, 599\u2013609 (2001).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2854_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03361-3","volume":"20","author":"T Li","year":"2022","unstructured":"Li, T. et al. Phosphorylated ATF1 at Thr184 promotes metastasis and regulates MMP2 expression in gastric cancer. J. Transl. Med. 20, 169 (2022).","journal-title":"J. Transl. Med."},{"key":"2854_CR61","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1093\/nar\/23.15.2848","volume":"23","author":"M Kobayashi","year":"1995","unstructured":"Kobayashi, M. & Kawakami, K. ATF-1CREB heterodimer is involved in constitutive expression of the housekeeping Na,K-ATPase alpha 1 subunit gene. Nucleic Acids Res. 23, 2848\u20132855 (1995).","journal-title":"Nucleic Acids Res."},{"key":"2854_CR62","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1007\/s10637-015-0273-z","volume":"33","author":"A Cercek","year":"2015","unstructured":"Cercek, A. et al. Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. Investig. N. Drugs 33, 1086\u20131092 (2015).","journal-title":"Investig. N. Drugs"},{"key":"2854_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52977-0","volume":"15","author":"Z Yang","year":"2024","unstructured":"Yang, Z. et al. Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma. Nat. Commun. 15, 9097 (2024).","journal-title":"Nat. Commun."},{"key":"2854_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01320-9","volume":"16","author":"G Ji","year":"2024","unstructured":"Ji, G. et al. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma. Genome Med 16, 49 (2024).","journal-title":"Genome Med"},{"key":"2854_CR65","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.ccell.2024.10.012","volume":"42","author":"CX Huang","year":"2024","unstructured":"Huang, C. X. et al. Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. Cancer Cell 42, 2082\u20132097.e2010 (2024).","journal-title":"Cancer Cell"},{"key":"2854_CR66","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41588-024-01998-y","volume":"57","author":"Y Yan","year":"2025","unstructured":"Yan, Y. et al. Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer. Nat. Genet. 57, 126\u2013139 (2025).","journal-title":"Nat. Genet."},{"key":"2854_CR67","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1158\/2159-8290.CD-21-0683","volume":"12","author":"V Kumar","year":"2022","unstructured":"Kumar, V. et al. Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer. Cancer Discov. 12, 670\u2013691 (2022).","journal-title":"Cancer Discov."},{"key":"2854_CR68","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ccell.2023.04.011","volume":"41","author":"J Li","year":"2023","unstructured":"Li, J. et al. Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. Cancer Cell 41, 1152\u20131169.e1157 (2023).","journal-title":"Cancer Cell"},{"key":"2854_CR69","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984\u2013997.e924 (2018).","journal-title":"Cell"},{"key":"2854_CR70","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.immuni.2024.02.007","volume":"57","author":"A Franken","year":"2024","unstructured":"Franken, A. et al. CD4(+) T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy. Immunity 57, 541\u2013558.e547 (2024).","journal-title":"Immunity"},{"key":"2854_CR71","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.ccell.2023.11.003","volume":"41","author":"J Chang","year":"2023","unstructured":"Chang, J. et al. Genomic alterations driving precancerous to cancerous lesions in esophageal cancer development. Cancer Cell 41, 2038\u20132050.e2035 (2023).","journal-title":"Cancer Cell"},{"key":"2854_CR72","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38, 675\u2013678 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2854_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02212-7","volume":"24","author":"BH Alsaafeen","year":"2025","unstructured":"Alsaafeen, B. H., Ali, B. R. & Elkord, E. Resistance mechanisms to immune checkpoint inhibitors: updated insights. Mol. Cancer 24, 20 (2025).","journal-title":"Mol. Cancer"},{"key":"2854_CR74","doi-asserted-by":"publisher","first-page":"844866","DOI":"10.3389\/fimmu.2022.844866","volume":"13","author":"BC Taylor","year":"2022","unstructured":"Taylor, B. C. & Balko, J. M. Mechanisms of MHC-I downregulation and role in immunotherapy response. Front. Immunol. 13, 844866 (2022).","journal-title":"Front. Immunol."},{"key":"2854_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217432","volume":"611","author":"S Kong","year":"2024","unstructured":"Kong, S. et al. Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy. Cancer Lett. 611, 217432 (2024).","journal-title":"Cancer Lett."},{"key":"2854_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60958-0","volume":"16","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Caffeine enhances antitumor T-cell activity by suppressing kynurenine pathway in colorectal cancer. Nat. Commun. 16, 5906 (2025).","journal-title":"Nat. Commun."},{"key":"2854_CR77","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","volume":"581","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto, K. et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 581, 100\u2013105 (2020).","journal-title":"Nature"},{"key":"2854_CR78","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1016\/j.cell.2023.07.016","volume":"186","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell 186, 3903\u20133920 e3921 (2023).","journal-title":"Cell"},{"key":"2854_CR79","doi-asserted-by":"publisher","first-page":"7285","DOI":"10.1016\/j.cell.2024.09.048","volume":"187","author":"L Herhaus","year":"2024","unstructured":"Herhaus, L. et al. IRGQ-mediated autophagy in MHC class I quality control promotes tumor immune evasion. Cell 187, 7285\u20137302 e7229 (2024).","journal-title":"Cell"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02854-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02854-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02854-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:01:09Z","timestamp":1784847669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02854-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2854"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02854-7","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"290"}}